R&D organization Battelle won a potentially $102.5 million 10-year research contract from the National Institutes of Health to carry out evaluation and testing services for vaccines and other biologics in development against infectious diseases. The work will be conducted at Battelle’s biosafety level 3 laboratories and new toxicology research facility in Ohio.
Battelle’s research will support the National Institute of Allergy and Infectious Diseases’ (NIAID) Division of Microbiology and Infectious Diseases' (DMID) development of vaccine and biologics as countermeasures against infectious diseases, including emerging and biodefense pathogens. The organization will carry out a range of preclinical, nonclinical, and clinical testing on a needs basis, including evaluating the efficacy, immunogenicity, and safety of vaccines, and analyzing samples from clinical trials.
“This contract is exactly the type of work we are built for at Battelle,” comments Barbara Kunz, president of the firm’s health and life sciences global business. “It spans several areas of expertise and supports government clients.”